N-substituted benzamides inhibit nuclear factor-kappaB and nuclear factor of activated T cells activity while

H Lindgren1, R W Pero, F Ivars

  • 1Department of Cell and Molecular Biology, Section for Immunology, BMC I:13, Lund University, S-221 84, Lund, Sweden. hanna.lindgren@immuno.lu.se

Molecular Immunology
|September 22, 2001
PubMed

Insights

Modified N-substituted benzamides can modulate immune responses by inhibiting or enhancing specific transcription factors. These compounds show potential as drug candidates for immune regulation.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • N-substituted benzamides have shown potential in inhibiting nuclear factor-kappaB (NF-kappaB) and inducing apoptosis.
  • Understanding their effects on T cell activation is crucial for developing immunomodulatory drugs.

Purpose of the Study:

  • To investigate the impact of N-substituted benzamides on transcriptional regulation in Jurkat T cells.
  • To assess their effects on key immune response transcription factors and gene promoters.

Main Methods:

  • Jurkat T cells were stimulated via TCR/CD28 or PMA/ionomycin.
  • Effects of N-substituted benzamides on NF-kappaB, NFAT, and AP-1 activity were analyzed.
  • Promoter activity of CD40 ligand (CD40L) and IL-2 genes was evaluated.

Main Results:

  • Acetylated N-substituted benzamides inhibited NF-kappaB and NFAT activity but enhanced AP-1 activity.
  • These compounds differentially modulated CD40L and IL-2 promoter activity.
  • Specific derivatives showed distinct effects on immune gene transcription.

Conclusions:

  • N-substituted benzamide derivatives can quantitatively and qualitatively modulate immune functions.
  • Acetylated variants show promise for targeted immune response modulation.
  • These compounds represent potential therapeutic candidates for immune-related disorders.

Related Concept Videos

Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...